Canine pancreatic response to intestinally perfused oligopeptides

1976 ◽  
Vol 231 (3) ◽  
pp. 678-681 ◽  
Author(s):  
JH Meyer ◽  
GA Kelly ◽  
RS Jones

Although older work indicated that luminal peptides are stimulants of pancreatic secretion, these earlier experiments were performed with crude peptide mixtures containing amino acids that are also known stimulants. Furthermore, no information was provided about size or composition of stimulating peptides. For this reason, the problem was reinvestigated with commercially synthesized oligopeptides in dogs equipped with chronic gastric and pancreatic fistulas. Synthetic peptides at 30 mM concentrations were perfused into the proximal bowel when luminal pancreatic proteases were reduced to undetectable concentrations and dogs were receiving intravenous exogenous secretin infusions. Increases in pancreatic outputs of protein and bicarbonate were measured. Of the peptides tested, only glycylphenylalanine, glycyltryptophan, and phenylalanylglycine stimulated, whereas both di- and triglycine were without effect. It was concluded that some, but not all, oligopeptides in the gut lumen are stimulants of pancreatic secretion.

1976 ◽  
Vol 231 (3) ◽  
pp. 682-691 ◽  
Author(s):  
JH Meyer ◽  
GA Kelly

Pancreatic bicarbonate and protein secretory responses to intestinally perfused proteins or digests of proteins were measured in dogs with chronic gastric and pancreatic fistulas when luminalpancreatic protease concentrations were reduced to undetectable levels. Protein digests were analyzed for amino acid content, and various other indirect met-ods were used to assess the composition of the digest mixtures. Of five undigested proteins, none evoked more pancreatic secretion than a control perfusion with saline. Peptic digestion of these same proteins converted four of them to polypeptides that were poten stimuli of a pancreatic juice similar in HCO3-/protein ratios to that evoked by luminal amino acids. Dialyzed peptic digests of one of the proteins, bovine serum albumin (BSA), retained potency. Likewise, digestion of BSA with endogenous or exogenous pancreatic proteases converted the protein to a stimulus about equipotent with the peptic digest, though the composition of the pancreatic digests differed markedly from that of the peptic digests. We conclude that a) luminal peptides of four or more amino acids can stimulate the pancreas and b) during protein alimentation a wide array of luminal protein products may evoke pancreatic secretion.


1976 ◽  
Vol 231 (3) ◽  
pp. 669-677 ◽  
Author(s):  
JH Meyer ◽  
GA Kelly ◽  
LJ Spingola ◽  
RS Jones

Pancreatic protein and bicarbonate outputs were measured in dogs with pancreatic fistulas receiving intravenous secretin while individual L-amino acids or mixtures of L-amino acids were perfused into proximal intestine, Both phenylalanine and tryptophan were potent stimuli of pancreatic secretion; alanine, leucine, and valine increased protein outputs but their effects were small and not statistically significant. Six other amino acids were ineffective. Tryptophan perfused together with phenylalanine augmented responses to phenylalanine; methionine, ineffective when perfused alone, did not alter responses to phenylalanine when perfused with the latter. Responses to phenylalanine perfused at concentrations above 8 mM were dependent on load and were mediated by lengths of proximal bowel greater than 10 cm.


2019 ◽  
Vol 19 (22) ◽  
pp. 1952-1961 ◽  
Author(s):  
J.C. Sobrinho ◽  
A.F. Francisco ◽  
R. Simões-Silva ◽  
A.M. Kayano ◽  
J.J. Alfonso Ruiz Diaz ◽  
...  

Background: Several studies have aimed to identify molecules that inhibit the toxic actions of snake venom phospholipases A2 (PLA2s). Studies carried out with PLA2 inhibitors (PLIs) have been shown to be efficient in this assignment. Objective: This work aimed to analyze the interaction of peptides derived from Bothrops atrox PLIγ (atPLIγ) with a PLA2 and to evaluate the ability of these peptides to reduce phospholipase and myotoxic activities. Methods: Peptides were subjected to molecular docking with a homologous Lys49 PLA2 from B. atrox venom modeled by homology. Phospholipase activity neutralization assay was performed with BthTX-II and different ratios of the peptides. A catalytically active and an inactive PLA2 were purified from the B. atrox venom and used together in the in vitro myotoxic activity neutralization experiments with the peptides. Results: The peptides interacted with amino acids near the PLA2 hydrophobic channel and the loop that would be bound to calcium in Asp49 PLA2. They were able to reduce phospholipase activity and peptides DFCHNV and ATHEE reached the highest reduction levels, being these two peptides the best that also interacted in the in silico experiments. The peptides reduced the myotubes cell damage with a highlight for the DFCHNV peptide, which reduced by about 65%. It has been suggested that myotoxic activity reduction is related to the sites occupied in the PLA2 structure, which could corroborate the results observed in molecular docking. Conclusion: This study should contribute to the investigation of the potential of PLIs to inhibit the toxic effects of PLA2s.


1993 ◽  
Vol 293 (1) ◽  
pp. 43-49 ◽  
Author(s):  
N M Rao ◽  
R Nagaraj

The interaction of synthetic peptides corresponding to wild-type signal sequences, and their mutants having charged amino acids in the hydrophobic region, with model and natural membranes has been studied. At high peptide concentrations, i.e. low lipid/peptide ratios, the signal peptides cause release of carboxyfluorescein (CF) from model membranes with lipid compositions corresponding to those of translocation-competent as well as translocation-incompetent membranes. Interestingly, mutant sequences, which were non-functional in vivo, caused considerable release of CF compared with the wild-type sequences. Both wild-type and mutant signal sequences perturb model membranes even at lipid/peptide ratios of 1000:1, as indicated by the activities of phospholipases A2, C and D. These studies indicate that such mutant signals are non-functional not because of their inability to interact with membranes, but due to defective targeting to the membrane. The signal peptides inhibit phospholipase C activity in microsomes, uncouple oxidative phosphorylation in mitochondria and increase K+ efflux from erythrocytes, and one of the mutant sequences is a potent degranulator of the mast cells. Both wild-type and mutant signal sequences have the ability to perturb vesicles of various lipid compositions. With respect to natural membranes, the peptides do not show any bias towards translocation-competent membranes.


Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 1269-1269
Author(s):  
Tor Olofsson ◽  
Stefan Skold ◽  
Urban Gullberg

Abstract We have shown that secreted enzymatically inactive dipeptide proforms of the hematopoietic serine proteases proteinase 3 (PR3), azurocidin and granzymes A, B, H, K, and M, are able to reduce the fraction of granulopoietic progenitors (CFU-GM) in S-phase, whereas human leukocyte elastase (HLE) and cathepsin G lack this ability. The objective of the present study was to map the specific sequence(s) of proPR3 responsible for the downmodulation of S-phase, and to elucidate the signaling pathways involved. The S-phase downmodulatory effect has a fast onset within 90 min, is reversible, non-cytotoxic and counteracted by G-CSF. The fast onset suggests a direct interruption of DNA-synthesis, i.e. an S-phase arrest. Synthetic peptides corresponding to N-terminal sequences of PR3, purified recombinant PR3 and HLE, as well as hybrid proteins constructed by an interchange of the di-propeptide and the first fourteen amino acids of the mature form of PR3 and HLE, thus creating PR3/HLE and HLE/PR3, respectively, were tested for their ability to reduce the S-phase fraction of granulopoeitic progenitors (CFU-GM). Results from synthetic peptides showed that the common N-terminal motif of PR3 and other serine proteases, i.e. IVGG or IIGG, downmodulate the S-phase of CFU-GM at 40–80 nM concentration. The dipeptide proform of HLE does not inhibit CFU-GM in S-phase, despite carrying the motif IVGG. However, if the N-terminal of HLE is presented by the HLE/PR3 hybrid protein, it is fully active, as well as the reciprocal hybrid PR3/HLE, whereas a mutant form PR3(G4R)/HLE and the tetrapeptide IVGR both are inactive. These findings demonstrate that the downmodulatory effect on CFU-GM in S-phase is mediated by the first four N-terminal amino acids IVGG of PR3, and also demonstrate that the activity is dependent on the configuration of the proform providing the correct presentation of this N-terminal motif. The S-phase arrest induced by proPR3 is mediated by a signal transduction pathway engaging phosphatidylinositol 3-kinase (PI3K), Akt/PKB, nitric oxide synthase (NOS), NO and ribonucleotide reductase. Inhibition of PI3K by wortmannin or LY294002, or Akt/PKB by 1L-6-hydroxymethyl-chiro-inositol 2-[(R)-2-O-methyl-3-O-octadecylcarbonate] abrogate the S-phase arrest induced by proPR3. The non-specific NOS-inhibitor N-monomethyl-L-arginine, the two iNOS-specific inhibitors 1400W or GW274150, or the nitric oxide scavenger carboxy-PTIO all abrogate the S-phase downmodulatory effect of proPR3. Furthermore, the effect of proPR3 is abolished by providing 2′-deoxyadenosine and 2′-deoxyguanosine to the cells, suggesting inhibition of ribonucleotide reductase, probably through direct inhibition by NO. The S-phase arrest induced by proPR3 is reproduced by SNAP, a cell-permeable NO-donor, an effect that is readily reversed by carboxy-PTIO or 2′-deoxyadenosine/2′-deoxyguanosine supplementation. The S-phase arrest induced by proPR3 is also reproduced by hydroxyurea (50 uM), a known inhibitor of ribonucleotide reductase, and is readily reversed by 2′-deoxyadenosine/2′-deoxyguanosine supplementation. The S-phase arrest induced by proPR3 or tetrapeptide IVGG has been verified by demonstration of a reduced incorporation of BrdU (bromo-deoxy-uridine) in purified myeloid progenitor cells isolated by fluorescence activated cell sorting. In conclusion, we provide evidence that the S-phase downmodulatory activity of proPR3 towards granulopoietic progenitors is an S-phase arrest caused by inhibition of ribonucleotide reductase by nitric oxide, mediated through PI3K, Akt/PKB, and NOS.


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 2200-2200
Author(s):  
Atsuko Igari ◽  
Takanori Moriki ◽  
Terumichi Nakagawa ◽  
Yusuke Yamaguchi ◽  
Mitsuru Murata

Abstract Abstract 2200 ADAMTS13 specifically cleaves multimeric von Willebrand factor (VWF) into smaller molecules to reduce its high reactivity with platelets. The disintegrin-like (D) domain, adjacent to the catalytic domain of ADAMTS13, plays an important role in the process of VWF cleavage. In this study, we aimed to elucidate critical peptide sequences in D-domain involved in the interaction with VWF. A series of partially overlapping peptide sequences, approximately 20 amino acids in length, covering the D-domain, were synthesized and the inhibitory effects on the catalytic activity of plasma ADAMTS13 was examined using FRETS-VWF73 assay. Consequently, some synthetic peptides were selected and the minimal length necessary for the inhibitory effect was determined as TFAREHLDMCQALSC (peptide323-337). Removal of the amino-terminal threonine diminished the inhibitory effect moderately, although deletion of the carboxyl-terminal cysteine abolished it completely. According to the amino acids alignment of ADAMTS family, this peptide sequence is not conserved, highlighting the specific role in the interaction with its substrate. From the recent analysis of crystal structure, amino-terminal half of the peptide323-337, TFAREHL (323-329), was disordered and designated as the variable (V) loop, which creates one of VWF-binding exosites (Akiyama, et al. Proc Natl Acad Sci USA. 2009; 106:19274-9). We hypothesized that the amino-terminal amino acids of the peptide323-337 contribute to VWF binding, whereas the carboxyl-terminal amino acids allow the structural stability of the peptide conformation. To evaluate the effect of carboxyl-terminal cysteine at 337, other synthetic peptides with alanine, serine, glycine or phenylalanine instead of the cysteine (C337A, C337S, C337G, or C337F) were tested about their inhibitory effects on the catalytic activity. Interestingly, C337A, C337S, C337G peptides exhibited slightly weaker inhibitory effects on VWF73 catalysis, although C337F peptide showed stronger inhibition than wild-type sequence, suggesting that the residue 337 regulates the characteristics of the peptide323-337. From the results of peptide screening, the amino- and carboxyl-terminal amino acids of the peptide323-337, TFAREHLDMCQALSC, likely play key roles in the inhibitory effects; therefore, the middle part of the sequence, HLDMC, was replaced by 5 alanines (AAAAA) or reversed sequence CMDLH. Surprisingly, the converted peptides still retained the equivalent level of inhibitory effects, indicating both sides of the amino- and carboxyl-terminal amino acids were especially significant in the interaction with VWF. In conclusion, we characterized the peptide sequence, TFAREHLDMCQALSC (323-337), in D-domain. The peptide clearly inhibited the cleavage of VWF73 and the both sides of amino- and carboxyl-terminal amino acids seemed especially important. The peptide sequence is supposed to bind to VWF for the precise cleavage in the process of proteolysis. By modifying this peptide sequence, such variant ADAMTS13 as gain-of-function recombinants might be developed, leading to an alternative anti-thrombotic drug. Disclosures: No relevant conflicts of interest to declare.


2011 ◽  
Vol 60 (1) ◽  
pp. 69-74 ◽  
Author(s):  
Hua Yang ◽  
Zhong-Hua Liu ◽  
Li-Ting Zhang ◽  
Jie Wang ◽  
Huan-Seng Yang ◽  
...  

Antibody responses can be useful markers of tuberculosis (TB) infection, especially in the screening of extra-pulmonary TB. MPT64 is an important antigen in Mycobacterium tuberculosis (MTB) infection and is used in serological diagnosis. However, large variability in the diagnostic accuracy of MPT64 as a serological tool has limited its application. Phage-displayed random peptide libraries have emerged as a powerful technique to select peptides (epitopes) or mimotopes that may serve as surrogate diagnostic markers in serological tests. In the present study, this method was employed to identify mimotopes of the MPT64 protein of MTB by screening a linear heptapeptide library with rabbit antibodies raised against MPT64 protein. Two antigenic mimotopes (M2 and M6) resembling B-cell epitopes of MPT64 were identified that bound the affinity purified anti-MPT64 polyclonal antibodies and competed with MPT64 for antibody binding. From the results of sequence alignment and a structure modelling figure of MPT64, the sequence of the 2nd to 5th amino acids (DSML) of M2 was totally consistent with the sequence of the 224th to 227th amino acids of MPT64 and the peptide is located on the surface of the space structure of MPT64, suggesting that it might be a linear epitope of MPT64. The recognition of both phage-displayed and synthetic peptides of M2 by the anti-MPT64 polyclonal antibodies also supported this. Although no recurring sequence and no analogue to MPT64 of M6 were found for sequence alignment, the recognition of both phage-displayed and synthetic peptides of M6 by the anti-MPT64 polyclonal antibodies indicated that it might be a mimotope of a conformational epitope of MPT64. According to the results of the reactivity of human sera with synthetic M2 and M6 peptides and MPT64, M2 showed a significantly higher AUC and sensitivity than M6 and MPT64, especially for the sera from sputum-negative TB patients, suggesting that the M2 mimotope may be useful in serological diagnostic testing for TB.


1992 ◽  
Vol 282 (2) ◽  
pp. 517-522 ◽  
Author(s):  
J Ghiso ◽  
T Wisniewski ◽  
R Vidal ◽  
A Rostagno ◽  
B Frangione

Two synthetic peptides with sequences identical with those of fragments of the extracellular domain of the Alzheimer's-disease amyloid precursor protein (APP) were used to raise antibodies. SP28 comprises positions 597-624 of the APP695 isoform, whereas SP41 extends towards the N-terminus (amino acids 584-624) and contains the entire SP28 peptide. Using e.l.i.s.a. and inhibition experiments we identified the two beta-turn-containing segments 602-607 and 617-624 as the epitopes recognized by anti-SP41 and anti-SP28 respectively. Both antibodies immunolabelled amyloid lesions in brains from Alzheimer's-disease patients and patients with related disorders, whereas they were unreactive in control brains. However, when probed on immunoblots, anti-SP28 failed to detect full-length APP from baculovirus-infected Sf9 cells, and anti-SP41 reacted weakly compared with other anti-APP antisera. The data suggest that these antibodies are directed to conformational epitopes not existent in the native molecules but present after alternative APP processing.


Sign in / Sign up

Export Citation Format

Share Document